Search
Selexipag
go.drugbank.com/drugs/DB11362ApprovedInvestigationalSelexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary
Deuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigational[A264108] The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway has been implicated in the pathophysiology of alopecia areata, as it regulates the expression of inflammatory … [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.
Avalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigationalFirst developed by Sanofi Genzyme, avalglucosidase alfa is a chemically modified version of [alglucosidase alfa], where synthetic bis-phosphorylated oligosaccharides were attached to the structure to improve … [L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease.
Olutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigational[A254736,A254741] Olutasidenib is orally bioavailable and capable of penetrating the blood-brain barrier, and is also being evaluated for the treatment of myelodysplastic syndrome (MDS), as well as solid … [A254726,L44256] Other IDH1 inhibitors, such as [ivosidenib], have also been approved for the treatment of relapsed or refractory AML.
Artesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigational[L890] Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin].[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099] … [L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria.
Synonyms: AS, butanedioic acid, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl] esterRasagiline
go.drugbank.com/drugs/DB01367ApprovedInvestigationalRasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Synonyms: RASMirdametinib
go.drugbank.com/drugs/DB07101ApprovedInvestigationalOn February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).
Enzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.
Milsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigational[A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes. … [L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]
Isoeugenol
go.drugbank.com/drugs/DB14188ApprovedIt is also a significant dermatologic sensitizer and allergen, and as a result has been restricted to 200 p.p.m. since 1998 according to guidelines issued by the fragrance industry [A34278]. … Isoeugenol is a commonly used fragrance added to many commercially available products, and occurs naturally in the essential oils of plants such as ylang-ylang.